Skip to main content
. 2013 Feb 22;8(2):e57871. doi: 10.1371/journal.pone.0057871

Figure 3. ICAD deficiency increases susceptibility to DMH-induced colon tumorigenesis.

Figure 3

WT and ICAD−/− mice received DMH injections once a week for 8 weeks. Mice were sacrificed 24 weeks later. (A) Diameter of tumors was assessed in the different experimental groups; n = 12. *, Difference from DMH-treated WT mice, p<0.01. (B) A gross examination of a large tumor detected in DMH-treated ICAD−/− mice. (C) H&E-stained colonic tissue with a large tumor from a DMH-treated ICAD−/− mouse; note the large necrotic cores (black arrows) and vascularization (yellow arrows). (D) PCNA expression in colon tumors from DMH-treated ICAD−/− mice as assessed by IHC. (E) H&E-stained section with a tumor from a DMH-treated ICAD−/− mouse with inflammatory cells (arrows) in the vicinity of the tumor. (F) MCP-1 and COX2 expression in colon tumors from DMH-treated ICAD−/− mice as assessed by IHC; the right panel is an IgG control.